Help us understand attention Learn more
Help us measure executive functions better Learn more
Find out if eye movements can diagnose disease Learn more
Help improve FTD diagnosis and patient care Learn more
Help us understand brain activity using fMRI Learn more
Improve dementia diagnosis and patient care Learn more
See if memantine can slow FTD symptoms Learn more
Donate your skin cells to create stem cells Learn more
Teach us about healthy aging Learn more
Help us create tools to measure social behavior Learn more
Improve diagnostic accuracy with PET Learn more
Amyloid PET in AD, FTD & PPA
- Inclusion criteria: Participants must be over the age of 50 and meet criteria for either frontotemporal dementia (FTD), Alzheimer's disease (AD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS) or healthy aging group. Patients are encouraged but not required to co-enroll in the Frontotemporal Dementia: Genes, Images and Emotions or New Approaches to Dementia Heterogeneity studies.
- Exclusion criteria: Participants cannot have a history of another major neurological disorder that could be a potential cause of dementia, active substance abuse, major systemic illnesses including active cancer, renal or liver failure, respiratory failure requiring oxygen, or use of current medications likely to affect the central nervous system (CNS). Patients are not eligible if they have had a nuclear imaging study (PET or SPECT) in the past year or are actively enrolled in an anti-amyloid clinical trial.